High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma.
Publication/Presentation Date
12-1-2019
Abstract
High-dose melphalan (MEL200) followed by autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma (MM). Bendamustine induces responses in MM resistant to other alkylators. Our prior Phase I trial adding bendamustine to MEL200 transplant conditioning resulted in no additional toxicity. We now report a single-arm, phase II study that evaluated the efficacy of bendamustine 225 mg/m
Volume
54
Issue
12
First Page
2027
Last Page
2038
ISSN
1476-5365
Published In/Presented At
Gomez-Arteaga, A., Mark, T. M., Guarneri, D., Christos, P. J., Gergis, U., Greenberg, J. D., Hsu, J., Mayer, S. A., Niesvizky, R., Pearse, R. N., Phillips, A. A., Rossi, A., Coleman, M., van Besien, K., & Shore, T. B. (2019). High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone marrow transplantation, 54(12), 2027–2038. https://doi.org/10.1038/s41409-019-0587-0
Disciplines
Medicine and Health Sciences
PubMedID
31190006
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article